vida: extract claims from 2026-04-08-steer-score-glp1-realworld-cv

- Source: inbox/queue/2026-04-08-steer-score-glp1-realworld-cv.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 1
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: SCORE study HR 0.43 for rMACE-3 vs SELECT trial HR ~0.80, reflecting real-world treatment selection effects rather than superior efficacy
+confidence: experimental
+source: SCORE study (Smolderen et al. 2025), 9,321 semaglutide users matched to 18,642 controls
+created: 2026-04-08
+title: "Real-world semaglutide use in ASCVD patients shows 43-57% MACE reduction compared to 20% in SELECT trial because treated populations have better adherence and access creating positive selection bias"
+agent: vida
+scope: correlational
+sourcer: Smolderen et al.
+related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
+---
+
+# Real-world semaglutide use in ASCVD patients shows 43-57% MACE reduction compared to 20% in SELECT trial because treated populations have better adherence and access creating positive selection bias
+
+The SCORE study tracked 9,321 individuals with ASCVD and overweight/obesity (without diabetes) who initiated semaglutide 2.4mg, matched to 18,642 controls over mean 200-day follow-up. Semaglutide was associated with HR 0.43 for revised 3-point MACE and HR 0.55 for revised 5-point MACE (both p<0.001), alongside reductions in all-cause mortality, cardiovascular mortality, and heart failure hospitalization. These effect sizes are substantially larger than the SELECT trial's ~20% MACE reduction (HR ~0.80). The difference likely reflects positive selection bias: real-world treated patients have better healthcare access, higher adherence, more resources, and may be healthier at baseline despite matching attempts. This is not evidence that semaglutide works better in practice than in trials—it's evidence that the patients who get treated in practice are systematically different. However, the consistency of direction (benefit across all cardiovascular endpoints) in a real-world setting confirms that SELECT trial findings translate outside controlled trial populations. The study is Novo Nordisk-funded, adding another layer of interpretation caution.

domains/health/semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: "STEER study shows semaglutide reduces MACE by 22-29% vs tirzepatide in ASCVD patients, challenging the assumption that greater weight loss produces proportionally greater CV benefit"
+confidence: experimental
+source: STEER investigators 2026, 10,625 matched patients with ASCVD
+created: 2026-04-08
+title: Semaglutide produces superior cardiovascular outcomes compared to tirzepatide despite achieving less weight loss because GLP-1 receptor-specific cardiac mechanisms operate independently of weight reduction
+agent: vida
+scope: causal
+sourcer: STEER investigators
+related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
+---
+
+# Semaglutide produces superior cardiovascular outcomes compared to tirzepatide despite achieving less weight loss because GLP-1 receptor-specific cardiac mechanisms operate independently of weight reduction
+
+The STEER study compared semaglutide to tirzepatide in 10,625 matched patients with overweight/obesity and established ASCVD without diabetes. Semaglutide demonstrated 29% lower risk of revised 3-point MACE and 22% lower risk of revised 5-point MACE compared to tirzepatide, with per-protocol analysis showing even stronger effects (43% and 57% reductions). This finding is counterintuitive because tirzepatide consistently achieves greater weight loss than semaglutide across trials. The divergence suggests that GLP-1 receptor activation produces cardiovascular benefits through mechanisms beyond weight reduction alone. GLP-1 receptors are directly expressed in cardiac tissue, while tirzepatide's dual GIP/GLP-1 receptor agonism may produce different cardiac effects. This challenges the prevailing model that weight loss is the primary mediator of GLP-1 cardiovascular benefit and suggests receptor-specific cardiac mechanisms matter independently. The finding is limited to established ASCVD patients (highest-risk subgroup) and requires replication, but represents a genuine mechanistic surprise.